202 related articles for article (PubMed ID: 14761135)
1. Fabry disease: enzyme replacement therapy.
Bongiorno MR; Pistone G; Aricò M
J Eur Acad Dermatol Venereol; 2003 Nov; 17(6):676-9. PubMed ID: 14761135
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
[TBL] [Abstract][Full Text] [Related]
3. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
Boutin M; Lavoie P; Menkovic I; Toupin A; Abaoui M; Elidrissi-Elawad M; Arthus MF; Fortier C; Ménard C; Maranda B; Bichet DG; Auray-Blais C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854306
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy in Fabry disease: a randomized controlled trial.
Schiffmann R; Kopp JB; Austin HA; Sabnis S; Moore DF; Weibel T; Balow JE; Brady RO
JAMA; 2001 Jun; 285(21):2743-9. PubMed ID: 11386930
[TBL] [Abstract][Full Text] [Related]
5. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous complications of Anderson-Fabry disease.
Giuseppe P; Daniele R; Rita BM
Curr Pharm Des; 2013; 19(33):6031-6. PubMed ID: 23448454
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease.
Levin M
Drugs Today (Barc); 2006 Jan; 42(1):65-70. PubMed ID: 16511611
[TBL] [Abstract][Full Text] [Related]
10. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
Schiffmann R; Ries M; Timmons M; Flaherty JT; Brady RO
Nephrol Dial Transplant; 2006 Feb; 21(2):345-54. PubMed ID: 16204287
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of and recent advances in therapy for Fabry disease.
Brady RO; Schiffmann R
JAMA; 2000 Dec; 284(21):2771-5. PubMed ID: 11105184
[TBL] [Abstract][Full Text] [Related]
12. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
14. Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice.
Xu S; Lun Y; Brignol N; Hamler R; Schilling A; Frascella M; Sullivan S; Boyd RE; Chang K; Soska R; Garcia A; Feng J; Yasukawa H; Shardlow C; Churchill A; Ketkar A; Robertson N; Miyamoto M; Mihara K; Benjamin ER; Lockhart DJ; Hirato T; Fowles S; Valenzano KJ; Khanna R
Mol Ther; 2015 Jul; 23(7):1169-1181. PubMed ID: 25915924
[TBL] [Abstract][Full Text] [Related]
15. Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease.
Hoffmann B; Reinhardt D; Koletzko B
Eur J Gastroenterol Hepatol; 2004 Oct; 16(10):1067-9. PubMed ID: 15371935
[TBL] [Abstract][Full Text] [Related]
16. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
Peces R; Olea T
Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
[TBL] [Abstract][Full Text] [Related]
17. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
[TBL] [Abstract][Full Text] [Related]
18. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
19. Enzyme replacement therapy in Fabry disease: clinical implications.
Breunig F; Knoll A; Wanner C
Curr Opin Nephrol Hypertens; 2003 Sep; 12(5):491-5. PubMed ID: 12920395
[TBL] [Abstract][Full Text] [Related]
20. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
